sacituzumab govitecan
gilead sciences
['mbc', 'sacituzumab govitecan', ' sg ']
sacituzumab govitecan vs treatment of physician s choice in hr+/her2- mbc. sg improved median pfs 5.5 vs 4.0 mo; hr, 0.66; 95% ci 0.53-0.83; p= 0.0003. provides evidence of clinical activity &amp; offers another potential treatment option. cost &amp; toxic need to be considered #asco2022 
Professor of Translational Oncology and Consultant Medical Oncologist